Insider · CIK 0001273885

Berger Franklin M

CIK 0001273885 Name as filed on the most recent filing

Filed as Berger Franklin M (39)

60 transaction lines · from 39 filings · filed 2008-01-24 to 2025-01-17 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

60 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2025-01-16 P, Open-market purchase Atea Pharmaceuticals, Inc.AVIR 33,614, acquired Open Form 4 filing 0000950170-25-006589
2025-01-16 P, Open-market purchase Atea Pharmaceuticals, Inc.AVIR 33,614, disposed Open Form 4 filing 0000950170-25-006489
2025-01-15 P, Open-market purchase Atea Pharmaceuticals, Inc.AVIR 47,885, acquired Open Form 4 filing 0000950170-25-006589
2025-01-15 P, Open-market purchase Atea Pharmaceuticals, Inc.AVIR 47,885, disposed Open Form 4 filing 0000950170-25-006489
2024-12-10 S, Open-market sale Atea Pharmaceuticals, Inc.AVIR 1,023,475, disposed Open Form 4 filing 0000950170-24-135930
2023-11-21 P, Open-market purchase Essa Pharma Inc.EPIX 133,274, acquired Open Form 4 filing 0000950170-23-065921
2023-11-03 P, Open-market purchase Essa Pharma Inc.EPIX 98,661, acquired Open Form 4 filing 0000950170-23-064584
2023-11-02 P, Open-market purchase Essa Pharma Inc.EPIX 321,000, acquired Open Form 4 filing 0000950170-23-064584
2022-12-21 S, Open-market sale Essa Pharma Inc.EPIX 2 lines 174,401, disposed Open Form 4 filing 0000899243-23-000914
2022-12-20 S, Open-market sale Essa Pharma Inc.EPIX 110,351, disposed Open Form 4 filing 0000899243-23-000914
2022-12-16 S, Open-market sale Essa Pharma Inc.EPIX 133,500, disposed Open Form 4 filing 0000899243-23-000914
2022-12-15 S, Open-market sale Essa Pharma Inc.EPIX 2 lines 235,800, disposed Open Form 4 filing 0000899243-23-000914
2022-12-14 S, Open-market sale Essa Pharma Inc.EPIX 75,000, disposed Open Form 4 filing 0000899243-23-000914
2022-11-22 P, Open-market purchase Rain Therapeutics Inc.RAIN 636,790, acquired Open Form 4 filing 0001104659-22-121849
2022-11-21 P, Open-market purchase Rain Therapeutics Inc.RAIN 351,000, acquired Open Form 4 filing 0001104659-22-121849
2022-11-14 S, Open-market sale Atea Pharmaceuticals, Inc.AVIR 83,352, disposed Open Form 4 filing 0000899243-22-035942
2022-11-11 S, Open-market sale Atea Pharmaceuticals, Inc.AVIR 131,333, disposed Open Form 4 filing 0000899243-22-035942
2022-11-08 P, Open-market purchase Rain Therapeutics Inc.RAIN 249,996, acquired Open Form 4 filing 0000899243-22-035691
2022-03-21 P, Open-market purchase Kezar Life Sciences, Inc.KZR 295,400, acquired Open Form 4 filing 0001209191-22-020584
2022-03-18 P, Open-market purchase Kezar Life Sciences, Inc.KZR 2 lines 1,004,400, acquired Open Form 4 filing 0001209191-22-020584
2021-09-21 P, Open-market purchase Rain Therapeutics Inc.RAIN 54,140, acquired Open Form 4 filing 0000899243-21-037351
2021-04-23 P, Open-market purchase Rain Therapeutics Inc.RAIN 2 lines 2,118,900, acquired Open Form 4 filing 0000899243-21-017113
2021-02-22 P, Open-market purchase Essa Pharma Inc.EPIX 1,539,000, acquired Open Form 4 filing 0001209191-21-017990
2020-11-03 P, Open-market purchase Atea Pharmaceuticals, Inc.AVIR 999,984, acquired Open Form 4 filing 0000899243-20-030331
2020-06-11 P, Open-market purchase Kezar Life Sciences, Inc.KZR 550,000, acquired Open Form 4 filing 0001209191-20-036045
2020-02-04 P, Open-market purchase Kezar Life Sciences, Inc.KZR 314,200, acquired Open Form 4 filing 0001209191-20-007050
2019-12-03 S, Open-market sale Five Prime Therapeutics, Inc.FPRX 191,560, disposed Open Form 4 filing 0001209191-19-059155
2019-12-02 S, Open-market sale Five Prime Therapeutics, Inc.FPRX 125,793, disposed Open Form 4 filing 0001209191-19-059155
2018-10-26 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 270,000, acquired Open Form 4 filing 0001209191-18-056298
2018-06-25 P, Open-market purchase Kezar Life Sciences, Inc.KZR 750,000, acquired Open Form 4 filing 0001209191-18-039668
2017-12-18 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 300,000, acquired Open Form 4 filing 0001209191-17-066244
2017-10-30 P, Open-market purchase Immune Design Corp.IMDZ 114,375, acquired Open Form 4 filing 0001209191-17-058672
2017-10-25 P, Open-market purchase Immune Design Corp.IMDZ 106,620, acquired Open Form 4 filing 0001209191-17-058081
2016-12-16 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 161,342, acquired Open Form 4 filing 0000899243-16-035955
2016-12-16 S, Open-market sale Immune Design Corp.IMDZ 327,330, disposed Open Form 4 filing 0001209191-16-156169
2016-12-15 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 285,626, acquired Open Form 4 filing 0000899243-16-035955
2016-09-14 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 899,990, acquired Open Form 4 filing 0000899243-16-029029
2016-04-22 P, Open-market purchase Five Prime Therapeutics IncFPRX 2 lines 247,340, acquired Open Form 4 filing 0001209191-16-115782
2016-04-19 P, Open-market purchase Five Prime Therapeutics IncFPRX 2 lines 286,607, acquired Open Form 4 filing 0001209191-16-115112
2016-02-17 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 200,000, acquired Open Form 4 filing 0000899243-16-013609
2015-04-21 P, Open-market purchase Immune Design Corp.IMDZ 662,500, acquired Open Form 4 filing 0001123292-15-000715
2015-01-28 P, Open-market purchase Five Prime Therapeutics IncFPRX 675,750, acquired Open Form 4 filing 0001123292-15-000224
2015-01-15 P, Open-market purchase Five Prime Therapeutics IncFPRX 130,065, acquired Open Form 4 filing 0001123292-15-000166
2015-01-14 P, Open-market purchase Five Prime Therapeutics IncFPRX 132,888, acquired Open Form 4 filing 0001123292-15-000166

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 47
  • Open-market sale 13
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. BERGER FRANKLIN M, insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001273885

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.